GSK (MEX:GSKN) Moat Score: 7/10 (As of Jun. 24, 2026)


MEX:GSKN GSK PLC MEX:GSKN
73 GF Score
Price MXN901.11
GF Value MXN818.82
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is GSK Moat Score?

GSK MEX:GSKN 73 Moat Score is 7 as of Jun. 24, 2026. GuruFocus rates MEX:GSKN with a GF Score™ of 73/100 and a GF Value™ of MXN818.82 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,033 Drug Manufacturers companies, GSK ranks better than 98.64% on this metric.

GSK has the Moat Score of 7, which implies that the company might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

GSK has Wide Moat: GSK PLC has an entry-level wide moat due to its strong brand, valuable intellectual property, and significant customer switching costs in the pharmaceutical industry. The company benefits from economies of scale, a superior distribution network, and consistent innovation through R&D.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes GSK might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

GSK  (MEX:GSKN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

GSK Moat Score Related Terms

MEX:GSKN vs LLY, JNJ, ABBV: Moat Score Comparison

For the Drug Manufacturers - General subindustry, GSK's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GSK Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GSK's Moat Score distribution charts can be found below:

* The bar in red indicates where GSK's Moat Score falls into.


MEX:GSKN
73GF Score
GSK PLC MEX:GSKN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 7 mean?
GSK (MEX:GSKN) has a Moat Score of 7 as of Jun. 24, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, GSK ranks #14 out of 1033 companies in the Drug Manufacturers industry, placing it in the top 1.4%.
Is GSK's Moat Score too high?
GSK's current Moat Score is 7. Based on the distribution chart, GSK ranks #14 out of 1033 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, GSK has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GSK's Moat Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GSK ranks #14 out of 1033 companies for Moat Score. This places GSK in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. GSK's current Moat Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (MEX:GSKN) is currently considered Fairly Valued. The stock's GF Value™ is MXN818.82, compared to a current price of MXN901.11 — trading 10% above its estimated fair value. The current Moat Score is 7. GSK's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For GSK (MEX:GSKN), the current Moat Score is 7 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GSK (MEX:GSKN) Overvalued in 2026?

Based on GuruFocus' analysis, GSK stock appears to be overvalued. The current stock price of MXN901.11 is trading 10% above its estimated GF Value™ of MXN818.82. GuruFocus considers GSK to be Fairly Valued.

Key valuation signals for MEX:GSKN:

  • Moat Score: 7
  • GF Value™: MXN818.82 vs. price of MXN901.11 (10% above fair value)
  • GF Score™: 73/100 with 1 warning sign

No single metric tells the full story. See the MEX:GSKN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GSK Business Description

Address 79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
73GF Score

Get the complete analysis for MEX:GSKN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN901.11
Price
MXN818.82
GF Value